See the DrugPatentWatch profile for Gadoterate
What is gadoterate meglumine?
Gadoterate meglumine is a gadolinium-based contrast agent (GBCA) used in MRI to help doctors see and assess abnormalities more clearly. It is given by injection before or during an MRI scan. [1]
What is it used for in MRI?
Gadolinium contrast in general is used to enhance the visibility of areas that may have abnormal blood flow or a disrupted barrier, such as certain tumors, inflammation/infection, and other lesions, depending on the body part and clinical question. The specific approved uses and scan protocols depend on the product labeling and country. [1]
How is it given and what should patients expect?
It is administered by healthcare professionals via an injection for the MRI exam. Timing and dose depend on the scan type and patient factors (including kidney function). [1]
Is gadoterate meglumine safe—who needs extra caution?
People with kidney problems need extra caution with any gadolinium-based contrast agent. Reduced kidney function can increase risk of rare complications. Clinicians typically assess kidney function before giving gadolinium contrast, especially in patients with known chronic kidney disease or at higher risk for kidney impairment. [1]
What are common side effects?
Like many medications, gadoterate meglumine can cause side effects. Mild effects (such as nausea, headache, or injection-site reactions) may occur, but the exact frequency and types of side effects are determined by the prescribing information and patient context. [1]
Does gadoterate meglumine have alternatives?
Yes. There are multiple GBCA options used for MRI (with different stability profiles and dosing considerations). Your clinician chooses based on the MRI indication, patient risk factors (particularly kidney function), and local availability. [1]
How does it compare with other gadolinium contrast agents?
Gadolinium agents differ in their chemical structure and stability, which can matter for safety in patients with impaired kidney function. The choice between agents is typically guided by clinical guidelines and product labeling in your region. [1]
Sources
- https://www.drugs.com/gadoterate-meglumine.html